English

CUMBERLAND PHARMACEUTICALS INC.

EDGAR

CPIX Current report (8-K) · filed 2026-10-26

Annual consolidated revenue for 2025: about USD 44.52M, using the latest reported figures. The previous period, 2024, was about USD 37.87M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

166 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 166458 USD Source

Operating margin

-1,898.65%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -3160461 USD Source
Revenue: 166458 USD Source

Operating cash flow

169 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 555765 USD Source
Operating Cash Flow: 387025 USD Source

Free cash flow

130 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 555765 USD Source
Operating Cash Flow: 387025 USD Source
Capital Expenditure: 38283 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 3.86 million USD 2026-06-30 Source
Exact value

3862402 USD
Long-term debt including current maturities: Not available
Shares outstanding: 15 million shares 2026-06-30 Source
Exact value

14983107 shares

Reported share-count change

0.15% · 23.2 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

14959937 shares · 2025-06-30· Source
14983107 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

31.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 8292362 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 13678651 USD · 2025-10-01 – 2025-12-31 Source
Revenue: 9131317 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 166458 USD · 2026-04-01 – 2026-06-30 Source

Net income

-10.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -1940764 USD · 2025-07-01 – 2025-09-30 Source
Net income: -1411692 USD · 2025-10-01 – 2025-12-31 Source
Net income: -3289639 USD · 2026-01-01 – 2026-03-31 Source
Net income: -4276377 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

746 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 4929498 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 4742318 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 4932522 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 4929498 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 387025 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: 555765 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: 387025 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-26.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+17.6%

Prior period

USD 37.87 million

2024-01-01 – 2024-12-31
Current period

USD 44.52 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

44521431 − 37867945 = 6653486 USD

37867945 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
44521431 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CUMBERLAND PHARMACEUTICALS INC. · 2025-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Year-over-year change in Revenue: 6653486 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 44521431 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1790162 Filing: 000108729426000020 Input fundies:Revenue: 37867945 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1791058 Filing: 000108729426000020
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 3.64 million

Prior period

−USD 6.48 million

2024-01-01 – 2024-12-31
Current period

−USD 2.84 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-2836128 − -6479770 = 3643642 USD

-6479770 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-2836128 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CUMBERLAND PHARMACEUTICALS INC. · 2025-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Year-over-year change in Net income: 3643642 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -2836128 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1814759 Filing: 000108729426000020 Input fundies:NetIncome: -6479770 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1815602 Filing: 000108729426000020
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 5.54 million

Prior period

−USD 612,186

2024-01-01 – 2024-12-31
Current period

USD 4.93 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

4932522 − -612186 = 5544708 USD

-612186 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
4932522 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2025-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Year-over-year change in Operating cash flow: 5544708 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 4932522 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1091045 Filing: 000108729426000020 Input fundies:OperatingCashFlow: -612186 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1091695 Filing: 000108729426000020
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+47.3%

Prior period

USD 66,461

2024-01-01 – 2024-12-31
Current period

USD 97,903

2025-01-01 – 2025-12-31

Exact inputs and evidence

97903 − 66461 = 31442 USD

66461 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
97903 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2025-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Year-over-year change in Capital expenditure: 31442 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 97903 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1093329 Filing: 000108729426000020 Input fundies:CapitalExpenditure: 66461 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1093919 Filing: 000108729426000020
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 44.52 million 100% of revenue
Operating costs Derived USD 47.31 million 106% of revenue
Operating income −USD 2.79 million −6.3% of revenue
Tax, interest and other Derived USD 44,135 0.1% of revenue
Net income −USD 2.84 million −6.4% of revenue

Cash

Operating cash flow USD 4.93 million 11% of revenue
Capital expenditure USD 97,903 0.2% of revenue
Free cash flow Derived USD 4.83 million 11% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 104% of revenue.
2017 Operating loss: operating costs were 110% of revenue.
2018 Operating loss: operating costs were 139% of revenue.
2019 Operating loss: operating costs were 129% of revenue.
2020 Operating loss: operating costs were 117% of revenue.
2021 Operating loss: operating costs were 121% of revenue.
2022 Operating loss: operating costs were 114% of revenue.
2023 Operating loss: operating costs were 124% of revenue.
2024 Operating loss: operating costs were 117% of revenue.
2025 Operating loss: operating costs were 106% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	32478185	33911316 Derived	-1433131	-488448 Derived	-944683	438606 Derived	Source 2016-01-01 – 2016-12-31: 32478185 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -1433131 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -944683 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 569478 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 130872 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	40376563	44457911 Derived	-4081348	3897285 Derived	-7978633	-833674 Derived	Source 2017-01-01 – 2017-12-31: 40376563 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -4081348 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -7978633 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -557714 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 275960 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	28803961	39976957 Derived	-11172996	-4209928 Derived	-6963068	2657168 Derived	Source 2018-01-01 – 2018-12-31: 28803961 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -11172996 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -6963068 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 3112737 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 455569 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	32407845	41696027 Derived	-9288182	-5750423 Derived	-3537759	2810154 Derived	Source 2019-01-01 – 2019-12-31: 32407845 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -9288182 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -3537759 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 3056356 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 246202 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	37441134	43822729 Derived	-6381595	-3042187 Derived	-3339408	5274244 Derived	Source 2020-01-01 – 2020-12-31: 37441134 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -6381595 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -3339408 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 5415061 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 140817 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	35985043	43662463 Derived	-7677420	-4169833 Derived	-3507587	6238911 Derived	Source 2021-01-01 – 2021-12-31: 35985043 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -7677420 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -3507587 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 6342443 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 103532 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	42010949	47715878 Derived	-5704929	-134688 Derived	-5570241	8351248 Derived	Source 2022-01-01 – 2022-12-31: 42010949 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -5704929 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -5570241 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 8453396 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 102148 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	39552507	49107168 Derived	-9554661	-3275341 Derived	-6279320	5812553 Derived	Source 2023-01-01 – 2023-12-31: 39552507 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -9554661 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -6279320 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: 6093821 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 281268 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	37867945	44300354 Derived	-6432409	47361 Derived	-6479770	-678647 Derived	Source 2024-01-01 – 2024-12-31: 37867945 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -6432409 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -6479770 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -612186 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 66461 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	44521431	47313424 Derived	-2791993	44135 Derived	-2836128	4834619 Derived	Source 2025-01-01 – 2025-12-31: 44521431 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -2791993 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -2836128 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 4932522 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 97903 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 44.5M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	32478185	Revenue: 32478185 Open source
20172017-12-31	Revenue	40376563	Revenue: 40376563 Open source
20182018-12-31	Revenue	28803961	Revenue: 28803961 Open source
20192019-12-31	Revenue	32407845	Revenue: 32407845 Open source
20202020-12-31	Revenue	37441134	Revenue: 37441134 Open source
20212021-12-31	Revenue	35985043	Revenue: 35985043 Open source
20222022-12-31	Revenue	42010949	Revenue: 42010949 Open source
20232023-12-31	Revenue	39552507	Revenue: 39552507 Open source
20242024-12-31	Revenue	37867945	Revenue: 37867945 Open source
20252025-12-31	Revenue	44521431	Revenue: 44521431 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

17.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	-3.1%	Revenue: 32478185 Open source Revenue: 33519051 Open source
20172017-12-31	Year over year	24.3%	Revenue: 40376563 Open source Revenue: 32478185 Open source
20182018-12-31	Year over year	-28.7%	Revenue: 28803961 Open source Revenue: 40376563 Open source
20192019-12-31	Year over year	12.5%	Revenue: 32407845 Open source Revenue: 28803961 Open source
20202020-12-31	Year over year	15.5%	Revenue: 37441134 Open source Revenue: 32407845 Open source
20212021-12-31	Year over year	-3.9%	Revenue: 35985043 Open source Revenue: 37441134 Open source
20222022-12-31	Year over year	16.7%	Revenue: 42010949 Open source Revenue: 35985043 Open source
20232023-12-31	Year over year	-5.9%	Revenue: 39552507 Open source Revenue: 42010949 Open source
20242024-12-31	Year over year	-4.3%	Revenue: 37867945 Open source Revenue: 39552507 Open source
20252025-12-31	Year over year	17.6%	Revenue: 44521431 Open source Revenue: 37867945 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -6.3% 2025

Net margin -6.4% 2025

Free cash flow margin 10.9% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-4.4%	Operating Income: -1433131 Open source Revenue: 32478185 Open source
20172017-12-31	Operating margin	-10.1%	Operating Income: -4081348 Open source Revenue: 40376563 Open source
20182018-12-31	Operating margin	-38.8%	Operating Income: -11172996 Open source Revenue: 28803961 Open source
20192019-12-31	Operating margin	-28.7%	Operating Income: -9288182 Open source Revenue: 32407845 Open source
20202020-12-31	Operating margin	-17%	Operating Income: -6381595 Open source Revenue: 37441134 Open source
20212021-12-31	Operating margin	-21.3%	Operating Income: -7677420 Open source Revenue: 35985043 Open source
20222022-12-31	Operating margin	-13.6%	Operating Income: -5704929 Open source Revenue: 42010949 Open source
20232023-12-31	Operating margin	-24.2%	Operating Income: -9554661 Open source Revenue: 39552507 Open source
20242024-12-31	Operating margin	-17%	Operating Income: -6432409 Open source Revenue: 37867945 Open source
20252025-12-31	Operating margin	-6.3%	Operating Income: -2791993 Open source Revenue: 44521431 Open source
20162016-12-31	Net margin	-2.9%	Net Income: -944683 Open source Revenue: 32478185 Open source
20172017-12-31	Net margin	-19.8%	Net Income: -7978633 Open source Revenue: 40376563 Open source
20182018-12-31	Net margin	-24.2%	Net Income: -6963068 Open source Revenue: 28803961 Open source
20192019-12-31	Net margin	-10.9%	Net Income: -3537759 Open source Revenue: 32407845 Open source
20202020-12-31	Net margin	-8.9%	Net Income: -3339408 Open source Revenue: 37441134 Open source
20212021-12-31	Net margin	-9.7%	Net Income: -3507587 Open source Revenue: 35985043 Open source
20222022-12-31	Net margin	-13.3%	Net Income: -5570241 Open source Revenue: 42010949 Open source
20232023-12-31	Net margin	-15.9%	Net Income: -6279320 Open source Revenue: 39552507 Open source
20242024-12-31	Net margin	-17.1%	Net Income: -6479770 Open source Revenue: 37867945 Open source
20252025-12-31	Net margin	-6.4%	Net Income: -2836128 Open source Revenue: 44521431 Open source
20162016-12-31	Free cash flow margin	1.4%	Revenue: 32478185 Open source Operating Cash Flow: 569478 Open source Capital Expenditure: 130872 Open source
20172017-12-31	Free cash flow margin	-2.1%	Revenue: 40376563 Open source Operating Cash Flow: -557714 Open source Capital Expenditure: 275960 Open source
20182018-12-31	Free cash flow margin	9.2%	Revenue: 28803961 Open source Operating Cash Flow: 3112737 Open source Capital Expenditure: 455569 Open source
20192019-12-31	Free cash flow margin	8.7%	Revenue: 32407845 Open source Operating Cash Flow: 3056356 Open source Capital Expenditure: 246202 Open source
20202020-12-31	Free cash flow margin	14.1%	Revenue: 37441134 Open source Operating Cash Flow: 5415061 Open source Capital Expenditure: 140817 Open source
20212021-12-31	Free cash flow margin	17.3%	Revenue: 35985043 Open source Operating Cash Flow: 6342443 Open source Capital Expenditure: 103532 Open source
20222022-12-31	Free cash flow margin	19.9%	Revenue: 42010949 Open source Operating Cash Flow: 8453396 Open source Capital Expenditure: 102148 Open source
20232023-12-31	Free cash flow margin	14.7%	Revenue: 39552507 Open source Operating Cash Flow: 6093821 Open source Capital Expenditure: 281268 Open source
20242024-12-31	Free cash flow margin	-1.8%	Revenue: 37867945 Open source Operating Cash Flow: -612186 Open source Capital Expenditure: 66461 Open source
20252025-12-31	Free cash flow margin	10.9%	Revenue: 44521431 Open source Operating Cash Flow: 4932522 Open source Capital Expenditure: 97903 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 4.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	569478	Operating Cash Flow: 569478 Open source
20172017-12-31	Operating cash flow	-557714	Operating Cash Flow: -557714 Open source
20182018-12-31	Operating cash flow	3112737	Operating Cash Flow: 3112737 Open source
20192019-12-31	Operating cash flow	3056356	Operating Cash Flow: 3056356 Open source
20202020-12-31	Operating cash flow	5415061	Operating Cash Flow: 5415061 Open source
20212021-12-31	Operating cash flow	6342443	Operating Cash Flow: 6342443 Open source
20222022-12-31	Operating cash flow	8453396	Operating Cash Flow: 8453396 Open source
20232023-12-31	Operating cash flow	6093821	Operating Cash Flow: 6093821 Open source
20242024-12-31	Operating cash flow	-612186	Operating Cash Flow: -612186 Open source
20252025-12-31	Operating cash flow	4932522	Operating Cash Flow: 4932522 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 4.8M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	438606	Operating Cash Flow: 569478 Open source Capital Expenditure: 130872 Open source
20172017-12-31	Free cash flow	-833674	Operating Cash Flow: -557714 Open source Capital Expenditure: 275960 Open source
20182018-12-31	Free cash flow	2657168	Operating Cash Flow: 3112737 Open source Capital Expenditure: 455569 Open source
20192019-12-31	Free cash flow	2810154	Operating Cash Flow: 3056356 Open source Capital Expenditure: 246202 Open source
20202020-12-31	Free cash flow	5274244	Operating Cash Flow: 5415061 Open source Capital Expenditure: 140817 Open source
20212021-12-31	Free cash flow	6238911	Operating Cash Flow: 6342443 Open source Capital Expenditure: 103532 Open source
20222022-12-31	Free cash flow	8351248	Operating Cash Flow: 8453396 Open source Capital Expenditure: 102148 Open source
20232023-12-31	Free cash flow	5812553	Operating Cash Flow: 6093821 Open source Capital Expenditure: 281268 Open source
20242024-12-31	Free cash flow	-678647	Operating Cash Flow: -612186 Open source Capital Expenditure: 66461 Open source
20252025-12-31	Free cash flow	4834619	Operating Cash Flow: 4932522 Open source Capital Expenditure: 97903 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

68.1% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	21.7%	Total Liabilities: 20283747 Open source Total Assets: 93404566 Open source
20172017-12-31	Liabilities / assets	31.4%	Total Liabilities: 29310711 Open source Total Assets: 93232312 Open source
20182018-12-31	Liabilities / assets	50.7%	Total Liabilities: 57123367 Open source Total Assets: 112693868 Open source
20192019-12-31	Liabilities / assets	51.1%	Total Liabilities: 53464030 Open source Total Assets: 104549283 Open source
20202020-12-31	Liabilities / assets	51.4%	Total Liabilities: 49589911 Open source Total Assets: 96463305 Open source
20212021-12-31	Liabilities / assets	49.6%	Total Liabilities: 41857820 Open source Total Assets: 84459798 Open source
20222022-12-31	Liabilities / assets	61.3%	Total Liabilities: 56951152 Open source Total Assets: 92925158 Open source
20232023-12-31	Liabilities / assets	64.2%	Total Liabilities: 52516206 Open source Total Assets: 81776075 Open source
20242024-12-31	Liabilities / assets	70.2%	Total Liabilities: 53037433 Open source Total Assets: 75583410 Open source
20252025-12-31	Liabilities / assets	68.1%	Total Liabilities: 52279770 Open source Total Assets: 76823992 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.01× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	4.43×	Current Assets: 65545264 Open source Current Liabilities: 14792263 Open source
20172017-12-31	Current assets / current liabilities	3.88×	Current Assets: 68684845 Open source Current Liabilities: 17694743 Open source
20182018-12-31	Current assets / current liabilities	2.13×	Current Assets: 59116037 Open source Current Liabilities: 27804224 Open source
20192019-12-31	Current assets / current liabilities	2.08×	Current Assets: 50163075 Open source Current Liabilities: 24150235 Open source
20202020-12-31	Current assets / current liabilities	1.95×	Current Assets: 49969592 Open source Current Liabilities: 25667446 Open source
20212021-12-31	Current assets / current liabilities	2.37×	Current Assets: 45688013 Open source Current Liabilities: 19278960 Open source
20222022-12-31	Current assets / current liabilities	1.6×	Current Assets: 45870210 Open source Current Liabilities: 28579832 Open source
20232023-12-31	Current assets / current liabilities	1.28×	Current Assets: 35714410 Open source Current Liabilities: 27982249 Open source
20242024-12-31	Current assets / current liabilities	1.15×	Current Assets: 36452158 Open source Current Liabilities: 31621729 Open source
20252025-12-31	Current assets / current liabilities	1.01×	Current Assets: 37060267 Open source Current Liabilities: 36744919 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 944,683 Exact value Exact value: -944683 USD 2016-01-01 – 2016-12-31: -944683 USD Inspect Net Income Open source Share or cite Citation for Net Income · CUMBERLAND PHARMACEUTICALS INC. · 2016-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Net Income: -944683 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -944683 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828019002785/cpix-20181231.htm#2104091 Filing: 000162828019002785 The citation records this snapshot. The page link may show a newer release later.	USD 569,478 Exact value Exact value: 569478 USD 2016-01-01 – 2016-12-31: 569478 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CUMBERLAND PHARMACEUTICALS INC. · 2016-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Operating Cash Flow: 569478 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 569478 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828019002785/cpix-20181231.htm#1493935 Filing: 000162828019002785 The citation records this snapshot. The page link may show a newer release later.	USD 130,872 Exact value Exact value: 130872 USD 2016-01-01 – 2016-12-31: 130872 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2016-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Capital Expenditure: 130872 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 130872 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828019002785/cpix-20181231.htm#1498569 Filing: 000162828019002785 The citation records this snapshot. The page link may show a newer release later.	USD 438,606 Calculation and evidence 569478 − 130872 USD Exact free cash flow: 438606 USD 2016-01-01 – 2016-12-31: 569478 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 130872 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2016-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Free cash flow: 438606 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 569478 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828019002785/cpix-20181231.htm#1493935 Filing: 000162828019002785 Input fundies:CapitalExpenditure: 130872 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828019002785/cpix-20181231.htm#1498569 Filing: 000162828019002785 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 7.98 million Exact value Exact value: -7978633 USD 2017-01-01 – 2017-12-31: -7978633 USD Inspect Net Income Open source Share or cite Citation for Net Income · CUMBERLAND PHARMACEUTICALS INC. · 2017-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Net Income: -7978633 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7978633 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828020003880/cpix-20191231.htm#2448707 Filing: 000162828020003880 The citation records this snapshot. The page link may show a newer release later.	−USD 557,714 Exact value Exact value: -557714 USD 2017-01-01 – 2017-12-31: -557714 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CUMBERLAND PHARMACEUTICALS INC. · 2017-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Operating Cash Flow: -557714 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -557714 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828020003880/cpix-20191231.htm#1681342 Filing: 000162828020003880 The citation records this snapshot. The page link may show a newer release later.	USD 275,960 Exact value Exact value: 275960 USD 2017-01-01 – 2017-12-31: 275960 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2017-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Capital Expenditure: 275960 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 275960 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828020003880/cpix-20191231.htm#1686977 Filing: 000162828020003880 The citation records this snapshot. The page link may show a newer release later.	−USD 833,674 Calculation and evidence -557714 − 275960 USD Exact free cash flow: -833674 USD 2017-01-01 – 2017-12-31: -557714 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 275960 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2017-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Free cash flow: -833674 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -557714 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828020003880/cpix-20191231.htm#1681342 Filing: 000162828020003880 Input fundies:CapitalExpenditure: 275960 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828020003880/cpix-20191231.htm#1686977 Filing: 000162828020003880 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 6.96 million Exact value Exact value: -6963068 USD 2018-01-01 – 2018-12-31: -6963068 USD Inspect Net Income Open source Share or cite Citation for Net Income · CUMBERLAND PHARMACEUTICALS INC. · 2018-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Net Income: -6963068 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6963068 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828021004654/cpix-20201231.htm#1960648 Filing: 000162828021004654 The citation records this snapshot. The page link may show a newer release later.	USD 3.11 million Exact value Exact value: 3112737 USD 2018-01-01 – 2018-12-31: 3112737 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CUMBERLAND PHARMACEUTICALS INC. · 2018-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Operating Cash Flow: 3112737 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 3112737 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828021004654/cpix-20201231.htm#1338738 Filing: 000162828021004654 The citation records this snapshot. The page link may show a newer release later.	USD 455,569 Exact value Exact value: 455569 USD 2018-01-01 – 2018-12-31: 455569 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2018-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Capital Expenditure: 455569 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 455569 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828021004654/cpix-20201231.htm#1342766 Filing: 000162828021004654 The citation records this snapshot. The page link may show a newer release later.	USD 2.66 million Calculation and evidence 3112737 − 455569 USD Exact free cash flow: 2657168 USD 2018-01-01 – 2018-12-31: 3112737 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 455569 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2018-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Free cash flow: 2657168 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 3112737 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828021004654/cpix-20201231.htm#1338738 Filing: 000162828021004654 Input fundies:CapitalExpenditure: 455569 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828021004654/cpix-20201231.htm#1342766 Filing: 000162828021004654 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 3.54 million Exact value Exact value: -3537759 USD 2019-01-01 – 2019-12-31: -3537759 USD Inspect Net Income Open source Share or cite Citation for Net Income · CUMBERLAND PHARMACEUTICALS INC. · 2019-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Net Income: -3537759 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3537759 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/cpix-20211231.htm#1953561 Filing: 000162828022005942 The citation records this snapshot. The page link may show a newer release later.	USD 3.06 million Exact value Exact value: 3056356 USD 2019-01-01 – 2019-12-31: 3056356 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CUMBERLAND PHARMACEUTICALS INC. · 2019-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Operating Cash Flow: 3056356 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 3056356 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/cpix-20211231.htm#1338124 Filing: 000162828022005942 The citation records this snapshot. The page link may show a newer release later.	USD 246,202 Exact value Exact value: 246202 USD 2019-01-01 – 2019-12-31: 246202 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2019-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Capital Expenditure: 246202 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 246202 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/cpix-20211231.htm#1342170 Filing: 000162828022005942 The citation records this snapshot. The page link may show a newer release later.	USD 2.81 million Calculation and evidence 3056356 − 246202 USD Exact free cash flow: 2810154 USD 2019-01-01 – 2019-12-31: 3056356 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 246202 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2019-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Free cash flow: 2810154 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 3056356 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/cpix-20211231.htm#1338124 Filing: 000162828022005942 Input fundies:CapitalExpenditure: 246202 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/cpix-20211231.htm#1342170 Filing: 000162828022005942 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 3.34 million Exact value Exact value: -3339408 USD 2020-01-01 – 2020-12-31: -3339408 USD Inspect Net Income Open source Share or cite Citation for Net Income · CUMBERLAND PHARMACEUTICALS INC. · 2020-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Net Income: -3339408 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3339408 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/cpix-20211231.htm#2367771 Filing: 000162828022005942 The citation records this snapshot. The page link may show a newer release later.	USD 5.42 million Exact value Exact value: 5415061 USD 2020-01-01 – 2020-12-31: 5415061 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CUMBERLAND PHARMACEUTICALS INC. · 2020-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Operating Cash Flow: 5415061 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 5415061 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/cpix-20211231.htm#1337076 Filing: 000162828022005942 The citation records this snapshot. The page link may show a newer release later.	USD 140,817 Exact value Exact value: 140817 USD 2020-01-01 – 2020-12-31: 140817 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2020-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Capital Expenditure: 140817 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 140817 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/cpix-20211231.htm#1341180 Filing: 000162828022005942 The citation records this snapshot. The page link may show a newer release later.	USD 5.27 million Calculation and evidence 5415061 − 140817 USD Exact free cash flow: 5274244 USD 2020-01-01 – 2020-12-31: 5415061 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 140817 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2020-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Free cash flow: 5274244 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 5415061 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/cpix-20211231.htm#1337076 Filing: 000162828022005942 Input fundies:CapitalExpenditure: 140817 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/cpix-20211231.htm#1341180 Filing: 000162828022005942 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 3.51 million Exact value Exact value: -3507587 USD 2021-01-01 – 2021-12-31: -3507587 USD Inspect Net Income Open source Share or cite Citation for Net Income · CUMBERLAND PHARMACEUTICALS INC. · 2021-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Net Income: -3507587 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3507587 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828023007727/cpix-20221231.htm#2141152 Filing: 000162828023007727 The citation records this snapshot. The page link may show a newer release later.	USD 6.34 million Exact value Exact value: 6342443 USD 2021-01-01 – 2021-12-31: 6342443 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CUMBERLAND PHARMACEUTICALS INC. · 2021-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Operating Cash Flow: 6342443 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 6342443 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828023007727/cpix-20221231.htm#1209529 Filing: 000162828023007727 The citation records this snapshot. The page link may show a newer release later.	USD 103,532 Exact value Exact value: 103532 USD 2021-01-01 – 2021-12-31: 103532 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2021-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Capital Expenditure: 103532 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 103532 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828023007727/cpix-20221231.htm#1212591 Filing: 000162828023007727 The citation records this snapshot. The page link may show a newer release later.	USD 6.24 million Calculation and evidence 6342443 − 103532 USD Exact free cash flow: 6238911 USD 2021-01-01 – 2021-12-31: 6342443 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 103532 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2021-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Free cash flow: 6238911 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 6342443 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828023007727/cpix-20221231.htm#1209529 Filing: 000162828023007727 Input fundies:CapitalExpenditure: 103532 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828023007727/cpix-20221231.htm#1212591 Filing: 000162828023007727 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 5.57 million Exact value Exact value: -5570241 USD 2022-01-01 – 2022-12-31: -5570241 USD Inspect Net Income Open source Share or cite Citation for Net Income · CUMBERLAND PHARMACEUTICALS INC. · 2022-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Net Income: -5570241 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5570241 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828024010725/cpix-20231231.htm#1729013 Filing: 000162828024010725 The citation records this snapshot. The page link may show a newer release later.	USD 8.45 million Exact value Exact value: 8453396 USD 2022-01-01 – 2022-12-31: 8453396 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CUMBERLAND PHARMACEUTICALS INC. · 2022-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Operating Cash Flow: 8453396 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 8453396 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828024010725/cpix-20231231.htm#1091635 Filing: 000162828024010725 The citation records this snapshot. The page link may show a newer release later.	USD 102,148 Exact value Exact value: 102148 USD 2022-01-01 – 2022-12-31: 102148 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2022-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Capital Expenditure: 102148 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 102148 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828024010725/cpix-20231231.htm#1093877 Filing: 000162828024010725 The citation records this snapshot. The page link may show a newer release later.	USD 8.35 million Calculation and evidence 8453396 − 102148 USD Exact free cash flow: 8351248 USD 2022-01-01 – 2022-12-31: 8453396 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 102148 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2022-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Free cash flow: 8351248 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8453396 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828024010725/cpix-20231231.htm#1091635 Filing: 000162828024010725 Input fundies:CapitalExpenditure: 102148 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828024010725/cpix-20231231.htm#1093877 Filing: 000162828024010725 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 6.28 million Exact value Exact value: -6279320 USD 2023-01-01 – 2023-12-31: -6279320 USD Inspect Net Income Open source Share or cite Citation for Net Income · CUMBERLAND PHARMACEUTICALS INC. · 2023-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Net Income: -6279320 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6279320 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828025011366/cpix-20241231.htm#1707161 Filing: 000162828025011366 The citation records this snapshot. The page link may show a newer release later.	USD 6.09 million Exact value Exact value: 6093821 USD 2023-01-01 – 2023-12-31: 6093821 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CUMBERLAND PHARMACEUTICALS INC. · 2023-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Operating Cash Flow: 6093821 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 6093821 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828025011366/cpix-20241231.htm#1076372 Filing: 000162828025011366 The citation records this snapshot. The page link may show a newer release later.	USD 281,268 Exact value Exact value: 281268 USD 2023-01-01 – 2023-12-31: 281268 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2023-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Capital Expenditure: 281268 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 281268 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828025011366/cpix-20241231.htm#1078614 Filing: 000162828025011366 The citation records this snapshot. The page link may show a newer release later.	USD 5.81 million Calculation and evidence 6093821 − 281268 USD Exact free cash flow: 5812553 USD 2023-01-01 – 2023-12-31: 6093821 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 281268 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2023-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Free cash flow: 5812553 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 6093821 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828025011366/cpix-20241231.htm#1076372 Filing: 000162828025011366 Input fundies:CapitalExpenditure: 281268 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000162828025011366/cpix-20241231.htm#1078614 Filing: 000162828025011366 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 6.48 million Exact value Exact value: -6479770 USD 2024-01-01 – 2024-12-31: -6479770 USD Inspect Net Income Open source Share or cite Citation for Net Income · CUMBERLAND PHARMACEUTICALS INC. · 2024-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Net Income: -6479770 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6479770 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1815602 Filing: 000108729426000020 The citation records this snapshot. The page link may show a newer release later.	−USD 612,186 Exact value Exact value: -612186 USD 2024-01-01 – 2024-12-31: -612186 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CUMBERLAND PHARMACEUTICALS INC. · 2024-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Operating Cash Flow: -612186 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -612186 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1091695 Filing: 000108729426000020 The citation records this snapshot. The page link may show a newer release later.	USD 66,461 Exact value Exact value: 66461 USD 2024-01-01 – 2024-12-31: 66461 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2024-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Capital Expenditure: 66461 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 66461 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1093919 Filing: 000108729426000020 The citation records this snapshot. The page link may show a newer release later.	−USD 678,647 Calculation and evidence -612186 − 66461 USD Exact free cash flow: -678647 USD 2024-01-01 – 2024-12-31: -612186 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 66461 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2024-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Free cash flow: -678647 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -612186 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1091695 Filing: 000108729426000020 Input fundies:CapitalExpenditure: 66461 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1093919 Filing: 000108729426000020 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 2.84 million Exact value Exact value: -2836128 USD 2025-01-01 – 2025-12-31: -2836128 USD Inspect Net Income Open source Share or cite Citation for Net Income · CUMBERLAND PHARMACEUTICALS INC. · 2025-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Net Income: -2836128 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2836128 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1814759 Filing: 000108729426000020 The citation records this snapshot. The page link may show a newer release later.	USD 4.93 million Exact value Exact value: 4932522 USD 2025-01-01 – 2025-12-31: 4932522 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CUMBERLAND PHARMACEUTICALS INC. · 2025-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Operating Cash Flow: 4932522 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4932522 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1091045 Filing: 000108729426000020 The citation records this snapshot. The page link may show a newer release later.	USD 97,903 Exact value Exact value: 97903 USD 2025-01-01 – 2025-12-31: 97903 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CUMBERLAND PHARMACEUTICALS INC. · 2025-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Capital Expenditure: 97903 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 97903 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1093329 Filing: 000108729426000020 The citation records this snapshot. The page link may show a newer release later.	USD 4.83 million Calculation and evidence 4932522 − 97903 USD Exact free cash flow: 4834619 USD 2025-01-01 – 2025-12-31: 4932522 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 97903 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CUMBERLAND PHARMACEUTICALS INC. · 2025-12-31 CUMBERLAND PHARMACEUTICALS INC. (edgar:1087294) Free cash flow: 4834619 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:27:54Z Snapshot: f6ec34747faba8a9caef7a4e798d0b5e88c01f28f1b6aae6995a4c51bfd27fc9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1087294?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4932522 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1091045 Filing: 000108729426000020 Input fundies:CapitalExpenditure: 97903 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm#1093329 Filing: 000108729426000020 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

78 filings · 5,114 latest values · 5,114 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001087294, 1087294, CPIX, edgar:1087294

Also known as CUMBERLAND PHARMACEUTICALS INC, CUMBERLAND PHARMACEUTICALS INC., Cumberland Pharmaceuticals Inc.

CUMBERLAND PHARMACEUTICALS INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation